Preclinical pharmacology of novel rain forest-derived anti-HIV compounds: costatolide (NSC-661122), 7,8-dihydrocostatolide (NSC-661123) and calanolide A (NSC-664737) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Preclinical pharmacology of novel rain forest-derived anti-HIV compounds: costatolide (NSC-661122), 7,8-dihydrocostatolide (NSC-661123) and calanolide A (NSC-664737) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 36:A1858 1995. Unique Identifier : AIDSLINE ICDB/95609633
Newman RA; Madden T; Univ. Texas M.D. Anderson Cancer Center, Houston, TX 77030

Abstract: Costatolide (C), dihydrocostatolide (DC) and calanolide A (CalA), derived from natural products, have demonstrated potent in vitro anti-HIV activity. As part of their preclinical development, analytical HPLC assays were developed for all three compounds. These have been applied to determination of pharmacokinetics in mice. PK data were obtained after iv and ip admin; the derived PK parameters following ip admin are shown in a table. Oral bioavailability of all three compounds was poor. After iv and ip administration, less than 5% of each product was found in urine. Tissue distribution and total elimination of [3H]CalA were presented and discussed.
Keywords: Animal Antiviral Agents/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS Biological Availability Chromatography, High Pressure Liquid Coumarins/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS Dose-Response Relationship, Drug HIV/*DRUG EFFECTS Mice Plant Extracts/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS ABSTRACTKWDanimalantiviralagents/administration&dosage/KWDpharmacokineticsbiologicalavailabilitychromatography,highpressureliquidcoumarins/administration&dosage/KWDpharmacokineticsdose-responserelationship,drughiv/KWDdrugeffectsmiceplantextracts/administration&dosage/KWDpharmacokineticsabstract
951230
M95C3237

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .